Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 10/20 | 0.63 |
| ▸ | MAPK14 | Q16539 | 10/20 | 0.63 |
| ▸ | KDR | P35968 | 8/20 | 0.63 |
| ▸ | SRC | P12931 | 6/20 | 0.58 |
| ▸ | TEK | Q02763 | 2/20 | 0.58 |
| ▸ | ABL1 | P00519 | 1/20 | 0.58 |
| ▸ | FYN | P06241 | 1/20 | 0.58 |
| ▸ | CSF1R | P07333 | 1/20 | 0.58 |
| ▸ | LYN | P07948 | 1/20 | 0.58 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.58 |
| ▸ | JAK3 | P52333 | 1/20 | 0.57 |
| ▸ | CDK4 | P11802 | 1/20 | 0.56 |
| ▸ | CCND1 | P24385 | 1/20 | 0.56 |
| ▸ | BRD4 | O60885 | 2/20 | 0.55 |
| ▸ | HCK | P08631 | 1/20 | 0.55 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4494570 | 0.89 | LCK (0.51) | LCKMAPK14KDRSRCTEK | |
| SCHEMBL30962860 | 0.88 | LCK (0.73) | LCKMAPK14KDRSRCTEK | |
| SCHEMBL4493726 | 0.86 | LCK (0.49) | LCKMAPK14KDRSRCTEK | |
| SCHEMBL4504472 | 0.85 | LCK (0.48) | LCKMAPK14KDRSRCTEK | |
| SCHEMBL4484592 | 0.84 | SIK1 (0.66) | LCKMAPK14KDRSRCTEK | |
| SCHEMBL31612065 | 0.83 | SRC (0.70) | LCKMAPK14SRCCDK4CCND1 | |
| SCHEMBL4504797 | 0.83 | PAK1 (0.57) | LCKMAPK14KDRSRC | |
| SCHEMBL4721744 | 0.81 | LCK (0.81) | LCKMAPK14KDRSRCTEK | |
| SCHEMBL29076144 | 0.81 | SRC (0.67) | LCKMAPK14SRCCDK4CCND1 | |
| SCHEMBL28228697 | 0.81 | LCK (0.60) | LCKMAPK14KDRCDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504396-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-03-17 | — | — | US | disclosed |
| EP-1648464-A1 | 2-AMINO-4-HYDROXY-5-PYRIMIDINCARBOXAMID DERIVATIVES AND RELATED COMPOUNDS AS T-CELL ACTIVATION INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS | AMGEN INC. (US) | 2006-04-26 | — | — | EP | disclosed |
| US-20050209221-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-09-22 | — | — | US | disclosed |
| WO-2005009443-A1 | 2-AMINO-4-HYDROXY-5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF T CELL ACTIVATION FOR THE TREATMENT OF INFLAMMATORY DISEASES | AMGEN INC. (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209221-A1 | Substituted heterocyclic compounds and methods of use | ICOS, CD4, HLA-DRB1 | LCK 33/4885MAPK14 3248/4885KDR 3785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.